MOESM3 of Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from Phase 2 and Phase 3 randomized, double-blind, placebo- and active-referenced studies

Abdel Hmissi (3905326); Bruce Martin (3905332); Charles Andrews (3905338); Dale Mohar (3905335); Denis Bourrelly (3905323); Frank Hampel (1412398); Jasper Dingemanse (3905320); Jay Bavel (3905344); Parisa Danaietash (3905341); Paul Ratner (3905317); Sara Mangialaio (3905329)

MOESM3 of Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from Phase 2 and Phase 3 randomized, double-blind, placebo- and active-referenced studies

Authors: Abdel Hmissi (3905326)
Bruce Martin (3905332)
Charles Andrews (3905338)
Dale Mohar (3905335)
Denis Bourrelly (3905323)
Frank Hampel (1412398)
Jasper Dingemanse (3905320)
Jay Bavel (3905344)
Parisa Danaietash (3905341)
Paul Ratner (3905317)
Sara Mangialaio (3905329)
Publication date: 1 April 2017
Publisher
Doi

Abstract

Additional file 3: Table S1. Setipiprant trough plasma concentrations across dose groups at the end* of weeks 1 and 2 during Phase 2 and Phase 3 trials

Similar works

Full text

Available Versions

FigShare

oai:figshare.com:article/48176...

Last time updated on 12/02/2018

Directory of Open Access Journals

oai:doaj.org/article:b297a392d...

Last time updated on 04/06/2019